Hemostemix's Social Media for Investors and Florida's No-Option Patients

Core Insights - Hemostemix Inc. is enhancing its investor awareness and social media strategies to promote its autologous stem cell therapy, VesCell™, targeting no-option patients in Florida suffering from various cardiovascular diseases [1][2] Investor Outreach Campaign - The company has sold forward $1,143,983 in Therapy Convertible Debenture year-to-date, indicating strong financial engagement [2] - Hemostemix has received multiple accolades, including the Biotechnology Company of the Year Award from Frost and Sullivan in 2007 and the World Economic Forum Technology Pioneer Award for VesCell™ [2] - The company is ramping up sales and patient engagement in Florida, with 498 treatments administered and 11 peer-reviewed publications supporting its clinical efficacy [2][7] Clinical Achievements - Hemostemix has completed seven clinical studies involving 318 subjects, with significant results published in peer-reviewed journals [7] - Phase II clinical trial results for chronic limb threatening ischemia (CLTI) showed a 0% mortality rate and an 83% wound healing rate among patients followed for up to 4.5 years [7] - A notable reduction in ulcerating wound size was reported, decreasing from a mean of 146 mm² to 0.48 mm² by the end of month three [9] Social Media and Communication Strategy - The company utilizes various platforms for targeted communication: Instagram for visual storytelling, LinkedIn for corporate updates, and YouTube for in-depth patient testimonials [6][9] - Opt-in SMS alerts and targeted emails are employed to keep investors informed about corporate milestones and clinical developments [5] Patient-Centric Focus - Real patient testimonials highlight improvements in cardiac function, pain reduction, and ulcer healing, making the treatment relatable [6] - The dual audience targeting strategy aims to recruit patients while educating investors about the potential upside of investing in Hemostemix [9]